Case studies
Every case below started with a biopsy from a partner vet school or referral hospital and ended with a ranked vaccine candidate list — with the full pipeline trace, provenance ledger entry, and clinical report available for review.
9-year-old Rottweiler. Standard amputation + carboplatin path. We ran the same tumor through DarkScan V2 to demonstrate the personalized-vaccine route — top candidate VSPSFSSTL (MAGEC1, IC50 26 nM).
Top epitope: VSPSFSSTL · MAGEC1 · IC50 26 nM · ~6h pipeline · ~$8 compute
Read the case →7-year-old Greyhound. Post-carboplatin recurrence on the contralateral side. Re-sequencing surfaced a distinct neoantigen profile dominated by TP53 R273H — top candidate GLLLPTDEC (IC50 38 nM). Shows what subclonal evolution looks like under chemotherapy pressure.
Top epitope: GLLLPTDEC · TP53 R273H · IC50 38 nM · ~6.4h pipeline · $8.14 compute
Read the case →6-year-old Golden Retriever. Treatment-naive DLBCL-like baseline before CHOP induction. Top candidate FNLPETVTL (BCL6 mutation, IC50 31 nM); 3 of top 5 from BCL6/MYC variants with human DLBCL homology.
Top epitope: FNLPETVTL · BCL6 mutation · IC50 31 nM · ~5.8h pipeline · $9.02 compute
Read the case →Recurrent cutaneous MCT with KIT mutation. End-to-end pipeline including targeted therapy comparators.
Coming as the work shipsPost-splenectomy adjuvant case. The most lethal canine cancer in our distribution — the case that proves the platform on the hardest indication.
Coming as the work shipsEditorial neutrality is a permanent commitment. When a pipeline run finds no actionable candidates, we publish that too. The negatives are how the community trusts the positives.